Clinical Trials Browser

Breast Neoplasms × IRX 2 × Clear all

NCT04373031 2025-12-02

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

Phase 2 Active not recruiting

12 enrolled 11 charts

Breast Neoplasms